Literature DB >> 9777184

Enhancement of antipsychoticlike properties of raclopride in rats using the selective serotonin2A receptor antagonist MDL 100,907.

M L Wadenberg1, P B Hicks, J T Richter, K A Young.   

Abstract

BACKGROUND: Selective suppression of conditioned avoidance response (CAR) is a standard animal screening test for predicting antipsychotic effect. Ability to suppress CAR is presumed to be due to antagonism at dopamine receptors, a property shared by all known antipsychotics.
METHODS: Using CAR behavior, in a conventional shuttle-box paradigm, as an index for antipsychotic efficacy, the effects of the selective serotonin2A receptor antagonist MDL 100,907 alone, and in combination with the dopamine D2 receptor antagonist raclopride, were studied in adult male Sprague-Dawley rats. Nonparametric procedures were employed for statistical evaluation.
RESULTS: MDL 100,907 (0.1-1.5 mg/kg, SC) alone did not suppress CAR in a manner predictive of antipsychotic activity; however, in the presence of an ED50 (0.14 mg/kg, SC) dose of raclopride, MDL 100,907 enhanced and prolonged the suppression of CAR. In the presence of a subthreshold (0.05 mg/kg, SC) dose of raclopride, MDL 100,907 induced a suppression of CAR.
CONCLUSIONS: The results suggest that treatment with a selective serotonin2A receptor antagonist alone may not produce a robust antipsychotic effect; however, a selective serotonin2A receptor antagonist in the presence of a minimal dopamine D2 receptor blocking action could potentially be an adjunctive therapy resulting in improved antipsychotic efficacy and fewer extrapyramidal symptoms.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9777184     DOI: 10.1016/s0006-3223(97)00424-1

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  8 in total

1.  Combined administration of an mGlu2/3 receptor agonist and a 5-HT 2A receptor antagonist markedly attenuate the psychomotor-activating and neurochemical effects of psychostimulants.

Authors:  Jason M Uslaner; Sean M Smith; Sarah L Huszar; Rashida Pachmerhiwala; Richard M Hinchliffe; Joshua D Vardigan; Pete H Hutson
Journal:  Psychopharmacology (Berl)       Date:  2009-08-26       Impact factor: 4.530

2.  Pharmacological characterization of social isolation-induced hyperactivity.

Authors:  Katrine Fabricius; Lone Helboe; Anders Fink-Jensen; Gitta Wörtwein; Björn Steiniger-Brach
Journal:  Psychopharmacology (Berl)       Date:  2010-12-31       Impact factor: 4.530

3.  Effects of 5-hydroxytryptamine 2C receptor agonist MK212 and 2A receptor antagonist MDL100907 on maternal behavior in postpartum female rats.

Authors:  Weihai Chen; Qi Zhang; Wenxin Su; Haorong Zhang; Yu Yang; Jing Qiao; Nan Sui; Ming Li
Journal:  Pharmacol Biochem Behav       Date:  2013-12-07       Impact factor: 3.533

4.  Effects of central activation of serotonin 5-HT2A/2C or dopamine D 2/3 receptors on the acute and repeated effects of clozapine in the conditioned avoidance response test.

Authors:  Min Feng; Jun Gao; Nan Sui; Ming Li
Journal:  Psychopharmacology (Berl)       Date:  2014-10-07       Impact factor: 4.530

5.  Enhancement of latent inhibition by two 5-HT2A receptor antagonists only when given at both pre-exposure and conditioning.

Authors:  L M McDonald; P M Moran; G N Vythelingum; M H Joseph; J D Stephenson; J A Gray
Journal:  Psychopharmacology (Berl)       Date:  2002-08-09       Impact factor: 4.530

6.  Adjunctive treatment with mianserin enhances effects of raclopride on cortical dopamine output and, in parallel, its antipsychotic-like effect.

Authors:  Charlotte Wiker; Love Linnér; Marie-Louise Wadenberg; Torgny H Svensson
Journal:  Neuropsychiatr Dis Treat       Date:  2005-12       Impact factor: 2.570

7.  Adjunctive treatment with mianserin enhances effects of raclopride on cortical dopamine output and, in parallel, its antipsychotic-like effect.

Authors:  Charlotte Wiker; Love Linnér; Marie-Louise Wadenberg; Torgny H Svensson
Journal:  Neuropsychiatr Dis Treat       Date:  2005-09       Impact factor: 2.570

8.  2-Bromoterguride-a potential atypical antipsychotic drug without metabolic effects in rats.

Authors:  Robert T Franke; Emilia Tarland; Heidrun Fink; Heinz H Pertz; Jan Brosda
Journal:  Psychopharmacology (Berl)       Date:  2016-06-17       Impact factor: 4.530

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.